Summary We compared the antitumour effects of glycosylated LT (gLT), nonglycosylated LT and TNF against a solid tumour in mice. We found that: (a) The systemic administration of gLT showed significant antitumour activity. These effects were, however, quite small in nude mice. Nonglycosylated LT and TNF attained the same degree of effectiveness as gLT, but at a 5-times higher dose. The serum half-life of gLT was 3-fold longer than that of nonglycosylated 
Summary We compared the antitumour effects of glycosylated LT (gLT), nonglycosylated LT and TNF against a solid tumour in mice. We found that: (a) The systemic administration of gLT showed significant antitumour activity. These effects were, however, quite small in nude mice. Nonglycosylated LT and TNF attained the same degree of effectiveness as gLT, but at a 5-times higher dose. The serum half-life of gLT was 3-fold longer than that of nonglycosylated longer than that of TNF. (b) The effect of gLT was significantly blocked by pretreatment with anti-asialo GM 1 antibody. Treatment with gLT produced a significant reduction in numbers of tumour-regional mononuclear cells, which in turn, produced increases intensive necrosis. (c) Mononuclear cells in the tumour tissues before gLT-injection were predominantly IL-2 receptor + /CD3 -cells and CD3 + cells. Pretreatment with the anti-asialo GM 1 antibody produced a drastic reduction of IL-2 receptor + /CD3 -cells. These findings suggest that the efficient antitumour effect of gLT is due to a longer serum half-life than that of nonglycosylated LT or TNF in vivo, and its function is largely mediated by IL-2 receptor+ /CD3 -cells.
Lymphotoxin (LT; TNF0) was first characterised as a biological factor generated in response to T cell activation that could mediate the cytolysis of tumour cells and other targets (Ruddle & Wakoman, 1967; Granger & Kolb, 1968; Dumonde et al., 1969; Rosenberg et al., 1973; Evans & Heinbaugh, 1981) . Later, human LT was purified and sequenced, and it was found to be about 30% homologous to tumour necrosis factor (TNF; TNFa) in its amino acid sequence (Aggarwal et al., , 1985a Pennica et al., 1984; Nedwin et al., 1985) . Furthermore, both LT and TNF were found to be linked to the human major histocompatibility complex (MHC) (Spies et al., 1986) , to share mainly a common cell-surface receptor (Aggarwal et al., 1985b; Patton et al., 1986) , and to have similar biological activities (Gray et al., 1984) . However, LT and TNF differ in some aspects, e.g., in their affinity to TNF receptors, in their adhesive properties related to neutrophils and hematopoietic cells, in their expression of MHC class I antigen, and so on (Locksley et al., 1987; Pober et al., 1987; Broudy et al., 1987; Andrews et al., 1990; Murphy et al., 1988; Oster et al., 1987; Cuturi et al., 1987; Beran et al., 1987) . It has also been reported that purified recombinant human TNF shows efficacy against tumours in vivo (Sohmura et al., 1986; Palladino, 1987; Manda et al., 1987; Asher et al., 1987; Watanabe et al., 1988; Inagawa et al., 1988) . However, there are few published data for in vivo studies of glycosylated human LT(gLT), (Khan et al., 1982; Papermaster et al., 1980; Ransom et al., 1982) , because the production of recombinant LT with sugar moieties was not achieved until quite recently. Human lymphotoxin genomic DNA has recently been cloned, and an efficient system for producing human gLT in Chinese hamster ovary cells has now been established in our laboratory (Nakagawa et al., 1991) . We have previously reported that gLT, unexpectedly, had weak cytotoxicity against tumour cells in vitro, but that it had a significant effect in vivo on solid tumours and metastases (Mikami et al., 1989; Funahashi et al., 1991) . Combination therapy with human interferon can induce greater synergistic efficacy than combinations of TNF and interferon (Kawatsu et al., 1990a 
Materials and methods

Mice
Female BALB/c and BALB/c nu/nu (-) mice, aged 6 weeks, were obtained from Japan SLC Inc. (Hamamatsu, Japan). They were fed a sterilised pellet diet and water ad libitum under pathogen-free conditions. Tumour A Meth A fibrosarcoma was kindly provided by the Faculty of Pharmaceutical Sciences, Teikyo University; it was maintained in ascites form in syngeneic BALB/c mice by weekly intraperitoneal (i.p.) passage.
LTand TNF Recombinant human gLT, produced by Chinese hamster ovary cells through the expression of human LT genomic DNA, was purified and characterised as described previously (Nakagawa et al., 1991) . Purified LT, consisting mostly of 171 amino acid residues (full length), was composed of three species with molecular masses of 25, 23 (major) and 21 kDa (very minor) as judged by sodium dodecyl sulfatepolyacrylamide gel electrophoresis (SDS-PAGE). Amino acid and sugar components of these gLT species were analysed, and it was found that (1) 25kDa LT has Leu-Pro-Gly-ValGly at N-terminus, carries both N-type sugar moieties (molecular ratio; Man: Fuc: Gal: GlucNAc: NANAc = 3: 1.2:2.4: 4.0:1.3) and mucin-type sugar moieties (molecular ratio; GalNAc: Gal: NANAc = 1: 1.06:1.14, and without Man), (2) 23 kDa carries N-type sugar moieties alone and comprises 80% of the preparation, and (3) 21 kDaLT is the same as the 23 kDa species except that it lacks 15 amino acid residues at the N-terminus, starts with Gln-His-Pro-Lys-Met sequence. The specific activity of the purified gLT prepara- .) The gLT preparation used in this study con-tained endotoxin at a concentration of less than 0.5 ngmg-' of protein. Mononuclear cell preparation from tumour tissue The treated tumour-bearing mice were killed 2h after the gLT-injection. Untreated control mice were used in parallel. Tumour mononuclear cells were prepared as described by Abo (1991) . Briefly, to obtain mononuclear cells, the tumours were cut into small pieces with scissors, pressed through 100-gauge stainless steel mesh, and supended in RPMI 1640 medium. After being washed once with the medium, the cell pellet was resuspended in 20 ml of the medium, and mononuclear cells were isolated by Ficoll-Isopaque density gradient centrifugation (1.090). In the mononuclear cell preparation method applied here, the proportion of contaminated phagocytes was negligible (<4%). Numbers of mononuclear cells were counted under a microscope, employing Turk's solution.
-& 3000- (0) were injected i.v. six times, once every other day, beginning 1 week after the inoculation. BALB/c nu/nu(-) mice d, also received gLT and saline in the same manner. Tumour weights represent the mean for five mice; bars indicate SD Significant differences (*P<0.05) between control and treated groups were analysed by Student's t-test.
Assay for permeability Mice with the Meth A tumour were injected i.v. with 0.2 ml of Evans' blue solution (10 mgml-' in saline) with or without gLT. Their solid tumours, which were removed 5 min after the injection, were dissolved with lNKOH (1 ml/solid tumour), extracted with 0.6NH2PO4/acetone (9 ml/solid tumour), and measured photometrically at 620 nm.
Histology
For immunocytochemical examinations, tumour tissues were fixed in periodate-lysine-paraformaldehyde (PLP) solution and embedded in OCT compound (Lab-Tek Products, Miles Laboratories Inc., Naperville. IL). Frozen sections were cut and incubated with the above-mentioned mAb, i.e., anti-1B TcR, anti-? 6 TcR, anti-Thyl.2, anti-CD4, anti-CD8 and anti-asialo GM1 mAb. After being washed in PBS, the sections were stained by the streptoavidin-biotin-complexperoxidase method and reacted with 3.3'-diaminobenzidine. Figure 1 . A dose-dependent growth-inhibitory effect of gLT was obtained in BALB/c (syngeneic) mice, and a significant effect at maximal dose achieved almost 70% (Figure 2) . The dose response curve of TNF was parallel to that of gLT, but nonglycosylated LT was not. However, both nonglycosylated LT and TNF attained the same effectiveness (ED50) at a dose and it was 5-times higher than that of gLT.
gLT, nonglycosylated LT and TNF were injected i.v. (bolus) into mice bearing Meth A sarcoma, and the decay in their serum biological activity was examined. As shown in Figure 3 , their factors decayed nearly monophasically in serum. The mean half-life of gLT was 1.7h, 3-fold longer than that of nonglycosylated (Figure 4 and Table I ). These mAb, which were injected i.v., beginning 2 days before tumour inoculation, clearly inhibited the antitumour effect of gLT. The inhibitory effect of anti-asialo GM1 mAb was significant, while those of the anti-CD4 and anti-CD8 mAb were partial. Although all mAb did not have significant effects, treatments with mAb tended not only to block the antitumour function of gLT, but also to block that in the control group without gLTtreatment at high doses.
The time course of the number of mononuclear cells was examined to determine whether the tumour-regional mononuclear cells were affected by gLT. The numbers of mononuclear cells did not change until 2h after the injection; 4h later, the number of these cells was significantly reduced, to one-eighth of that noted before gLT-injection ( Figure 5 ). We also examined changes in the permeability of the tumour vessels. Evans' blue solution was administered i.v. after gLTinjection. Local permeability increased by almost 120% 1 h after the administration of gLT. However, the permeability rapidly lessened at 2h, followed by gradual reduction to 50%-60%, which continued until 6h. Thus, gLT peripheral area was observed 2 h after gLT-injection; after this time, these cells almost disappeared, and intensive necrosis was induced at 24h ( Figure 6 ). Time after LT injection (h) Figure Meth A sarcoma (3 x 105cells) was inoculated i.d. into BALB/c mice. gLT (1.6 x 105 LMU kg-') was injected i.v. six times, once every other day, beginning I week after inoculation. Anti-asialo GM1 mAb, anti-CD4 mAb and anti-CD8 mAb were injected intravenously at the indicated dose (1-3 mg/mouse) six times, once every other day, beginning 2 days before the inoculation of Meth A sarcoma. Each tumour weight value represents the average of four to five mice; bars indicate standard deviations. Significant differences (*P <0.05) between control and treated groups were analysed by Student's t-test. 
Analysis of tumor-regional mononuclear cells before gLT-injection
In the short-term experiment described above, no increase of tumour-regional mononuclear cells was observed. Therefore, we carried out immuno-cytochemical staining with mAb to confirm whether mononuclear cells involved with the gLT function were actually present in tumour tissues before gLTinjection. As shown in Figure 7 , various populations of mononuclear cells, i.e., a ,B-T cell receptor (TcR) +, y 6 -TcR+, Thy-1.2+, CD4+, CD8+, and asialo GMI+ cells, were shown in these tissues. We also carried out a two-colour immunofluorescence test, using FITC-conjugated anti-IL-2 receptor P and PE-conjugated anti-CD3 mAb, to compare IL-2 receptor and CD3 antigen expression patterns in the mononuclear cells. The mononuclear cells in BALB/c mice were shown to predominantly consist of IL-2 receptor + /CD3-(35%) and CD3 + cells (31%) (upper panel in Figure 8 ). Pretreatment with the anti-asialo GMI mAb produced to a significant reduction in IL-2 receptor+/ CD3-cells, one-seventh of that in non-treated mice; however, this pretreatment did not produce a reduction in the CD3+ population. Next, a two-colour immunofluorescence test, using anti-CD4 and anti-CD8 mAb, was also performed to determine the proportion of the subpopoulation of CD3 + cells (lower panel in Figure 8 ). The proportion of CD4 + to CD8 + cells was 3:1, and no effect of the anti-asialo GM 1 mAb was observed in these subpopulations. The two-colour immunofluorescence test was also performed in nude mice (Table II) . However, all populations of mononuclear cells in these animals were low, being equivalent to one-third of those in syngeneic mice. Thus, the mononuclear cells involved with gLT function, i.e., IL-2 receptor + /CD3-, CD4 + cells and CD8 + cells were found to be present in the tumour tissues, and the proportions of these cells were are quite low in immune-defective nude mice.
Discussion
In this study, we investigated the usefulness of human gLT conjugated with sugar moieties against a solid tumour in mice and we examined the population of mononunclear cells involved with its action.
The growth-inhibitory activity of gLT against a syngeneic tumour was greater than that of TNF, which conversely had a stronger growth-inhibitory activity than that of gLT in vitro (Funahashi et al., 1991) . In vivo a 5-fold greater dose of TNF than of gLT was required to produce equivalent effectiveness (Figures 1 and 2) . A similar phenomenon was observed in combination with y-interferon, which showed no significant indications of acting additively or synergistically (Kawatsu et al., 1990a) . However, gLT, which is about 30% homologous to TNF in amino acid sequence, has no disulfide bridges, and a different structure of the central part of the molecule from TNF in addition to possessing sugar moieties. Therefore, we prepared nonglycosylated LT to test the effects of sugar moieties. Although the dose-response curve of nonglycosylated LT was quite different from gLT or TNF, nonglycosylated LT also required a five-fold greater dose than gLT to obtain equivalent effectiveness. It has been shown that LT and TNF share a common receptor and have almost the same affinity for their cell-surface receptors on 3T3 LI adipocytes and U-937 histocytic lymphoma cells (Aggarwal et al., 1985b; Patton et al., 1986) . However, it has also reported that the affinity of non-glycosylated LT for TNF receptors on human endothelial cells is markedly lower than that of TNF, and that the LT competes for TNF receptors at almost 100-fold greater concentrations than TNF (Locksley et al., 1987) . We have also demonstrated that the half-life of gLT depends upon the N-type sugar moieties, not upon mucintype sugar moieties (Kawatsu et al., 1990b) . In the present study we have shown that nonglycosylated LT has a 3-fold shorter serum half-life than gLT whilst the half-life of TNF is 1/22 that of gLT (Figure 3) . We are still uncertain as to whether the affinity of glycosylated LT for TNF receptors on human cells is different from nonglycosylated LT or TNF; we do not know enough about the details of the differences from the structure of N-type sugar moieties, e.g. differences between bi-and tri-antennas, or effects of their sialic acids, to be able to explain why gLT expresses more efficient therapeutic activity. However, these findings suggest that the differences between gLT and nonglycosylated LT or TNF may arise from the longer half-life of gLT in serum, and the differences of half-life in serum may be due to the affinity for TNF receptors on endothelial cells.
The antitumour mechanisms of LT and TNF in vivo are still not clear, but it has been suggested that these include direct cytotoxic effects against tumour cells as well as indirect effects, including augmentation of the host-mediated immune response and modulation of endothelial cell hemostatic properties at the tumour site (Old, 1985) . Therefore, we examined the population of mononuclear cells involved with its action. The antitumour effect of gLT was significantly blocked by anti-asialo GM1 mAb, and depletion of CD4 + and CD8 + cells induced a partial reduction in the antitumour activity of gLT ( Figure 4 and Table I ). This phenomenon has been observed to greater extent in a pulmonary metastasis model (Funahashi et al., 1991 (3 x IO' cells) was inoculated i.d. into BALB/c mice (eight mice/group). Anti-asialo GM 1 mAb (1.5 mg/mouse) was injected i.v. five times, once every other day, beginning 2 days before tumour-inoculation. A control group was injected with saline in the same manner. Seven days after the inoculation, the mononuclear cells were isolated from the tumour tissues, pooled, and analysed by immunofluorescence tests using the following mAb: FITC-conjugated anti-II-2 receptor P and PE-conjugated aliquots of anti-CD3 (upper panel), and FITC-conjugated anti-CD4 and PE-conjugated aliquots of anti-CD8 (lower panel). BALB/c nu/nu(-) 14 0.7* 12 9.9* 4 ± 0.0* 2 ± 0.0* Meth A sarcoma (3 x 105 cells) was inoculated i.d. into both BALB/c mice and BALB/c nu/nu(-) mice (eight mice/group). Seven days later, the mononuclear cells (MNC) were isolated from tumour tissues, pooled, and then analysed by immunofluorscence tests, using the following mAb: FITC-conjugated anti-IL-2 receptorp and PE-conjugated aliquots of anti-CD3, and FITC-conjugated anti-CD4 and PE-conjugated aliquots of anti-CD8. Each value for % fluorescence-positive cells represents the mean ± SD of duplicate or triplicate determinations. Significant differences (*P <0.05) between BALB/c and BALB/c nu/nu(-) mice were analysed by Student's t-test.
Treatment with anti-CD3 mAb plus IL-2 induces the augmentation of CD4+ cells (Garbrecht et al., 1988; Londei et al., 1988) , and the generation of an optimal CD8+ cellcytotoxic response requires help from CD4 + cells (Kern, 1988) . It is well known that NK cells interact with T cells (CD3 + cells) through cytokines such as interferons and IL-2.
These findings suggest that CD4 + orCD8 + cells stimulated by gLT may also enhance the action of asialo GM1 + cells. Anti-asialo GM1 mAb produced a significant reduction in tumour-regional IL-2 receptor + /CD3 -cells (Figures 7 and  8 ), indicating that a major population of IL-2 receptor + / CD3 -mononuclear cells is shared by asialo GM1 + cells, thus there is the possibility of interaction between asialo GM 1+ cells and CD4 + or CD8 + cells in the tumour area. We found that gLT produced reductions in tumour regional mononuclear cells and changes in the permeability of tumour vessels with a similar time course (Figures 5 and 6 ). The role of this transient increase in permeability is still uncertain, but the reduction in permeability may explain the action of gLT in inducing tumour necrosis and tumour regression. The reduction in permeability may have been due not only to the direct effect of gLT, but also to the indirect effect of tumourregional mononuclear cells being stimulated by gLT. Since (1) anti-asialo GM1 mAb abolished the function of gLT, (2) smaller tumour regional necrosis and lower efficacy are seen in nude mice stimulated by gLT, and (3) low proportion of both tumour-regional IL-2 receptor + /CD3 -cells and CD3 + cells are observed in nude mice (Table II) . In any case it is obvious that, for effector cells to express their antitumour effect, the presence of these cells in certain quantities, in addition to their activation, is necessary. The findings described above also suggest that a combination of gLT and LAK-therapy may be more efficient against established tumours than therapy with either agent alone.
In conclusion, we have shown that the efficient antitumour effect of gLT with N-type sugar moities is due to a longer serum half-life than that of nonglycosylated LT or TNF in vivo, and its activity is largely dependent on the function of IL-2 receptor + /CD3-cells.
